- Decision is likely to delay a possible broad roll-out of the vaccine for between three and five years. It was expected that the vaccine would be recommended for use by 2017.
- The experts recommended that the demonstration projects be conducted on children aged five to 17 months. The projects could involve up to 1 million children and are likely to take three to five years.
- The vaccine is being assessed as a complementary malaria control tool that could potentially be added to — but not replace — the core package of proven preventive, diagnostic and treatment measures.